PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

625 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 14 from 1 topic.Sort: Newest | Oldest
GOLD 2023 COPD Report: Major Revisions from the Global Initiative for COPD
🔓 Free Teaser Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate

The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.

2019 ATS/IDSA Community-Acquired Pneumonia Guideline: Practice-Defining Updates
🔓 Free Teaser Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
Also in Pulmonology / Respiratory

The 2019 ATS/IDSA CAP guideline introduces major shifts in diagnostic and empiric therapy strategies for adult patients.

Montelukast Linked to Higher ADHD and Conduct Risk Versus Inhaled Steroids
Analysis Pediatrics Confirmatory Grade: Low
Also in Psychiatry / Psychopharmacology, Pulmonology / Respiratory

Montelukast may increase neuropsychiatric risks in children with asthma.

Isavuconazole for chronic pulmonary aspergillosis: tolerability and TDM-guided dosing
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Also in Pulmonology / Respiratory, Pharmacokinetics / TDM

Standard isavuconazole dosing often overshoots in chronic pulmonary aspergillosis, so early troughs can guide a step down to 100 mg daily.

Pharmacotherapy Reshapes Obstructive Sleep Apnea Management Toward Endotype-Driven Care
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Pulmonology / Respiratory

New drug options show promise for improving sleep apnea treatment beyond CPAP.

First-Trimester Inhaled Steroid Continuation Shows No Excess Pregnancy Risk
Analysis Women's Health / Reproductive Confirmatory Grade: Moderate
Also in Pulmonology / Respiratory

Continue ICS during pregnancy to safely control asthma.

MARCH: Mucoactive Agents Fail and Harm in Ventilated Patients
★ Editor's Pick Analysis Critical Care / ICU Practice-changing Grade: Moderate
Also in Pulmonology / Respiratory

Carbocisteine and hypertonic saline did not shorten ventilation in nearly 2,000 ICU patients, and both added harm.

AAIITO Expert Consensus Reframes Mild-to-Moderate Asthma Toward Proactive Control
Consensus Statement Pulmonology / Respiratory Confirmatory Grade: Low

Expert consensus offers new guidelines for mild-to-moderate asthma management.

Pharmacist Inhaler Review Cuts Readmissions in COPD, Not Overall
Analysis Pulmonology / Respiratory Hypothesis-generating Grade: Moderate

Pharmacist intervention cuts COPD readmissions effectively.

No Mortality Advantage for Higher-Dose Steroids in Pneumonia
Analysis Critical Care / ICU Confirmatory Grade: Low
Also in Infectious Disease / Antimicrobials, Pulmonology / Respiratory

Lower and higher corticosteroid doses both reduce pneumonia mortality.

JCS/JPCPHS 2025 Guideline Reshapes Pulmonary Hypertension and VTE Management
★ Editor's Pick Guideline Cardiology Practice-changing Grade: Moderate
Also in Anticoagulation / Hematology, Pulmonology / Respiratory

New 2025 guidelines set standards for PH and DVT management.

GOLD 2026 COPD Strategy: Mepolizumab Enters the Algorithm
Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate

GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.

GINA 2021: Two-Track Asthma Strategy Replaces SABA-Only Reliever Reliance
Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate

GINA 2021 formalizes ICS-formoterol as the preferred reliever across all adult/adolescent steps and adds new pediatric and Step 5 options.

2016 ATS/IDSA HAP/VAP Guideline: HCAP Retired, Antibiograms Prioritized
Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Low
Also in Critical Care / ICU, Pulmonology / Respiratory

The 2016 ATS/IDSA update reshapes empiric antibiotic selection, de-escalation, and duration of therapy for hospital-acquired and ventilator-associated pneumonia around local resistance data and pharmacokinetic optimization.